Atopic Dermatitis | Pfizer | B7451015
Pharmaceutical Company/Sponsor:
Pfizer
Code:
B7451015
Title:
A PHASE 3 MULTI-CENTER, LONG-TERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB, WITH OR WITHOUT TOPICAL MEDICATIONS, ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS
Type:
Interventional
Phase:
3
Condition/Disease:
Atopic Dermatitis
Intervention(s)/Treatment(s):
Drug: Abrocitinib 100 mg
Drug: Abrocitinib 200 mg
Drug: Placebo
Status:
Enrolling by Invitation
Link for Additional Information:
